Indication
Adenocarcinoma of the Esophagogastric Junction
3 clinical trials
4 products
9 drugs
Clinical trial
Metabolic and Molecular Response Evaluation for the Individualization of Therapy in Adenocarcinomas of the Gastroesophageal JunctionStatus: Completed, Estimated PCD: 2020-08-07
Drug
mFOLFOX6Drug
EpirubicinProduct
CapecitabineDrug
fluorouracilProduct
CarboplatinDrug
TiragolumabClinical trial
Perioperative Chemotherapy (FLOT Protocol) Compared To Neoadjuvant Chemoradiation (CROSS Protocol) in Patients With Adenocarcinoma of the EsophagusStatus: Active (not recruiting), Estimated PCD: 2024-05-01
Drug
DocetaxelDrug
AN0025Clinical trial
Perioperative Immunotherapy vs. Chemo-immunotherapy Stratified by Early Response Evaluation in Patients With Advanced Gastric Cancer (GC) and Adenocarcinoma of the Esophago-gastric Junction (AEG)Status: Active (not recruiting), Estimated PCD: 2024-03-01
Drug
T-VECDrug
relatlimabDrug
FOLFOXIRIProduct
5-FluorouracilProduct
Folic acid